Nutex Health (NUTX) Q2 2026 earnings summary

Executive summary

• Net income attributable to shareholders rose to $65.8M for Q2 2026 (EPS $9.38), reversing a prior year loss, with six-month net income at $112.6M (EPS $15.87), driven by lower stock-based compensation and reduced arbitration costs.

• Patient visits increased 9.6% year-over-year in Q2 2026, with same-hospital visits up 6.3%.

• Achieved strong operational and financial results in Q2 2026, with improved profitability despite a year-over-year revenue decline due to normalization of IDR-related revenue recognition.

• Continued expansion of hospital development pipeline, with three new facilities expected to open in late 2026 and additional projects planned for 2027 and beyond.

• Regulatory and legal wins reinforced the integrity of the IDR process, supporting fair reimbursement and reducing arbitration-related costs.

Financial highlights

• Q2 2026 revenue decreased 13.6% year-over-year to $210.8M; six-month revenue fell 6.3% to $427.2M, mainly due to prior period IDR catch-up.

• Net income for Q2 2026 was $65.8M (vs. $-17.7M in Q2 2025); first half net income surged to $112.6M (vs. $3.5M in 2025).

• Adjusted EBITDA for Q2 2026 rose to $90M (Q2 2025: $71.6M); first half Adjusted EBITDA up to $147.5M.

• Gross profit margin improved to 67% in Q2 2026 (vs. 51.2% in Q2 2025); operating income for Q2 2026 was $121.7M (vs. $33.7M in Q2 2025).

• Cash and equivalents at June 30, 2026, were $205.2M, up from $185.6M at year-end 2025; net cash from operations for the first half was $109.7M, up 40% year-over-year.

Outlook and guidance

• Hospital opening cadence remains at 3–5 per year, with three new hospitals planned for late 2026 and ongoing evaluation of new opportunities.

• Revenue per visit expected to remain stable in the $4,000–$4,200 range, with potential upside from increased inpatient and procedural volumes.

• Arbitration-related costs projected to decrease 25–30% due to regulatory and contract changes, including CMS fee reductions.

• Management expects to finish the year strong, with further cost reductions from arbitration process changes.

• Ongoing regulatory and legal uncertainty around the No Surprises Act and IDR process may continue to impact revenue recognition and financial volatility.